Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Post-Brexit device rules risk the UK falling behind
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Medtechs that book the most sales per employee face the greatest losses
Welcome to the calm before the Covid-19 storm.
Orthopaedics companies’ nightmare quarter
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Covid-19 takes a toll on medtech’s first quarter
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
The crucial trials Medtronic has had to pause
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
